NRx Pharmaceuticals (NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
February 9, 2024 8:30 AM ESTCompanies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality
Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for this trial is anticipated in Q2 of this year."
Productive partnership aims to accelerate NRX-101 to patients in need
Lotus further reported revenues of NT$1996, a 45% month over month increase.
RADNOR, Pa.,... More
